Respiratory disease Archives

News and Trends 15 Feb 2017

Actelion’s key Drug linked to Deaths, prompting EMA Investigation

Johnson & Johnson is certainly counting on its recent acquisition of the European biotech success Actelion to upgrade its top line. Now Actelion’s key product, Uptravi, may be facing some safety issues. One of Actelion’s new products, Uptravi, was launched last January against pulmonary arterial hypertension (PAH) and – with a €150000 ($160,000) price tag – it makes up a […]

February 15, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 1 Feb 2017

Stem Cell Therapy for Sepsis in Pneumonia advances to Phase II

TiGenix has treated the first patient in a new early-stage clinical trial to test its candidate Cx611 as a treatment for sepsis in patients with pneumonia. TiGenix, based in Belgium, develops stem cell therapies derived from donors. This morning, the first patient was treated in a Phase Ib/IIa clinical trial for its candidate therapy Cx611 in […]

February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 26 Jan 2017

Europe’s Largest Biotech Actelion Seals the Deal with J&J for €28B

Actelion will be acquired by J&J for a whopping €27.9B, and its early R&D pipeline will be spun out into a new Switzerland-based outfit. The wait is over folks: Actelion, the largest biotech in Europe and one of the only 9 to make it to the billion-euro club in 2016, has just announced its acquisition by Johnson & Johnson for a […]

January 26, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 24 Jan 2017

Smart Nebulizers for Children with Asthma are Underway

Vectura has received FDA approval to start testing a smart device to improve asthma therapies in children. Vectura, based in the UK, develops inhaled delivery technology for diseases that affect air tracts, such as cystic fibrosis, or influenza. The company has now received an investigational new drug (IND) approval from the FDA to study a […]

January 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Jan 2017

A Placebo beats the Largest European Biotech in Phase III

Actelion’s lead drug Opsumit has missed its primary endpoint in Phase III. What are the consequences for the biggest independent biotech in Europe? Actelion is a leader in treatments for pulmonary arterial hypertension (PAH). However, results from a Phase III trial evaluating Opsumit (macitentan) in patients with PAH due to Eisenmenger Syndrome have revealed that the drug […]

January 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Jan 2017

Evotec launches New Biotech to tackle the Most Deadly Diseases

Evotec has backed the foundation of Fibrocor, a Canadian company that will work on fibrosis, the underlying cause of some of the most deadly diseases. Fibrocor was launched yesterday in Toronto with €2M (CDN 2.8M) from the successful German biotech CRO Evotec and the Canadian non-profit MaRS Innovation. Evotec will provide all drug discovery activities […]

January 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 17 Jan 2017

Nanoparticles from Car Tailpipes could Activate Viruses in the Lungs

Nanoparticles produced by burning fossil fuels could promote viral infections by activating latent viruses in our lungs; what are the consequences? We all know that breathing the traffic smoke is not good for our health. Now, researchers from the Helmholtz Zentrum in Munich have discovered a process that makes it even more dangerous than initially […]

January 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Jan 2017

An Antibody to reduce Hospitalizations of Children starts Phase IIb trials

Ablynx has treated its first patient in a new trial targeting RSV infections, the main cause of children hospitalizations. Ablynx, one of the few European biotechs that made it into JP Morgan this year, develops nanobodies derived from llamas. The Belgian company announced yesterday that its candidate ALX-0171 has entered testing in Phase IIb as a treatment […]

January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

sloth crossing the road Scenic Shutterbug fi

News and Trends 2 Dec 2016

Stories We Didn’t Cover: MDMA in Phase III, Another Death for Carmat

Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week. Sanofi has acquired Warp Drive Bio’s antibiotics program, which was born out of […]

December 2, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 28 Nov 2016

Finally a Cure for the Common Cold? And it’s Needle-free!

Mucosis is starting Phase I trials for SynGEM, a needle-free vaccine against RSV, which causes 200k deaths per year and has a huge cost for both healthcare and the economy. Mucosis is a biotech from the Netherlands developing needle-free vaccines. The company has now initiated the first human trial for SynGEM, a nasal spray vaccine against […]

November 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Nov 2016

Fighting for the next Asthma Blockbuster: Italy gets in the way of Novartis

Chiesi has bought Atopix Therapeutics and stepped into the fight for the next asthma blockbuster. Can it take on Novartis in the competition for what is expected to grow to a €24B market in 2024? Chiesi is an Italian pharma with a strong focus on respiratory diseases. To strengthen its pipeline, the company has acquired the […]

November 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 24 Oct 2016

Here comes the First-ever Combination Therapy for Multiple Sclerosis

Actelion is overcoming the upcoming expiration of one of its most profitable patents and it’s using its strong position to make the leap into the crowded market of multiple sclerosis with the first-ever combination therapy. Actelion is one of the top billion-euro Biotechs in Europe and a leader in pulmonary arterial hypertension (PAH). Although the patent for […]

October 24, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Respiratory disease

Actelion’s key Drug linked to Deaths, prompting EMA Investigation

Stem Cell Therapy for Sepsis in Pneumonia advances to Phase II

Europe’s Largest Biotech Actelion Seals the Deal with J&J for €28B

Smart Nebulizers for Children with Asthma are Underway

A Placebo beats the Largest European Biotech in Phase III

Evotec launches New Biotech to tackle the Most Deadly Diseases

Nanoparticles from Car Tailpipes could Activate Viruses in the Lungs

An Antibody to reduce Hospitalizations of Children starts Phase IIb trials

Stories We Didn’t Cover: MDMA in Phase III, Another Death for Carmat

Finally a Cure for the Common Cold? And it’s Needle-free!

Fighting for the next Asthma Blockbuster: Italy gets in the way of Novartis

Here comes the First-ever Combination Therapy for Multiple Sclerosis

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!